Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Vertex's success since the early 2010s is due to its work in CF. The company famously markets the only approved medicines that target the underlying causes of this condition. Thanks to its monopoly, ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the fourth quarter and year ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of vaso-occlusive crises (VOCs).

Casgevy and Lyfgenia, the two cell-based gene therapies approved by the FDA, utilise the CRISPR/Cas9 genome editing technology. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...